Neuronetics (STIM) Competitors $4.23 +0.22 (+5.44%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. MDXG, TNDM, BLFS, PLSE, INMD, IRMD, KMTS, SIBN, BBNX, and EMBCShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include MiMedx Group (MDXG), Tandem Diabetes Care (TNDM), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Kestra Medical Technologies (KMTS), SiBone (SIBN), Beta Bionics (BBNX), and Embecta (EMBC). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors MiMedx Group Tandem Diabetes Care BioLife Solutions Pulse Biosciences InMode iRadimed Kestra Medical Technologies SiBone Beta Bionics Embecta MiMedx Group (NASDAQ:MDXG) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has more volatility & risk, MDXG or STIM? MiMedx Group has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Does the media prefer MDXG or STIM? In the previous week, MiMedx Group had 3 more articles in the media than Neuronetics. MarketBeat recorded 16 mentions for MiMedx Group and 13 mentions for Neuronetics. MiMedx Group's average media sentiment score of 0.81 beat Neuronetics' score of -0.35 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is MDXG or STIM more profitable? MiMedx Group has a net margin of 8.84% compared to Neuronetics' net margin of -43.47%. MiMedx Group's return on equity of 23.03% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets MiMedx Group8.84% 23.03% 17.09% Neuronetics -43.47%-156.36%-35.69% Which has preferable valuation and earnings, MDXG or STIM? MiMedx Group has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiMedx Group$348.88M2.98$42.42M$0.2133.50Neuronetics$74.89M3.73-$43.71M-$1.13-3.74 Do analysts prefer MDXG or STIM? MiMedx Group presently has a consensus price target of $12.00, suggesting a potential upside of 70.58%. Neuronetics has a consensus price target of $5.00, suggesting a potential upside of 18.26%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe MiMedx Group is more favorable than Neuronetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Neuronetics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals hold more shares of MDXG or STIM? 79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 8.7% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryMiMedx Group beats Neuronetics on 13 of the 16 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$282.33M$6.75B$5.45B$9.65BDividend YieldN/A1.35%3.99%4.14%P/E Ratio-3.7824.2029.9924.99Price / Sales3.7354.78375.7976.03Price / CashN/A20.5535.9458.58Price / Book8.815.588.125.66Net Income-$43.71M$178.18M$3.25B$265.39M7 Day Performance-4.34%-0.13%0.96%2.45%1 Month Performance23.63%-4.95%2.71%1.81%1 Year Performance126.10%7.17%28.13%24.02% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics1.163 of 5 stars$4.23+5.4%$5.00+18.3%+114.4%$282.33M$74.89M-3.78180Earnings ReportAnalyst ForecastMDXGMiMedx Group2.6656 of 5 stars$7.15-0.1%$12.00+67.8%+13.4%$1.06B$348.88M34.05870TNDMTandem Diabetes Care4.0784 of 5 stars$15.42+0.1%$32.71+112.2%-68.9%$1.03B$982.95M-5.552,650Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBLFSBioLife Solutions3.1191 of 5 stars$20.89+0.4%$31.00+48.4%-6.4%$995.21M$82.25M-72.03440News CoveragePositive NewsEarnings ReportAnalyst ForecastPLSEPulse Biosciences3.9574 of 5 stars$15.07+2.2%$22.00+46.0%+7.0%$992.29M$700K0.00140Positive NewsUpcoming EarningsINMDInMode3.338 of 5 stars$14.07+2.4%$18.04+28.2%-13.2%$868.49M$394.82M5.70480IRMDiRadimed4.2152 of 5 stars$70.69+6.8%$72.00+1.9%+59.5%$841.36M$73.24M43.64110News CoverageHigh Trading VolumeKMTSKestra Medical Technologies1.5166 of 5 stars$15.49+0.7%$27.33+76.5%N/A$789.75M$59.82M0.00300Positive NewsSIBNSiBone4.0545 of 5 stars$17.90+2.9%$22.50+25.7%+15.6%$741.07M$167.18M-27.97350Positive NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeBBNXBeta Bionics2.4926 of 5 stars$16.42+0.1%$22.56+37.4%N/A$712.91M$65.12M0.00294EMBCEmbecta4.7818 of 5 stars$9.79-1.7%$19.00+94.1%-25.2%$582.09M$1.08B10.882,100News CoverageEarnings ReportDividend AnnouncementGap Up Related Companies and Tools Related Companies MDXG Competitors TNDM Competitors BLFS Competitors PLSE Competitors INMD Competitors IRMD Competitors KMTS Competitors SIBN Competitors BBNX Competitors EMBC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
